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adenocarcinoma (EAC). Patients with BE usually are identiﬁed by endoscopy, which is expen-
sive. The Cytosponge, which collects tissue from the esophagus noninvasively, could be a cost-
effective tool for screening individuals with gastroesophageal reﬂux disease (GERD) who are at
increased risk for BE. We developed a model to analyze the cost effectiveness of using the
Cytosponge in ﬁrst-line screening of patients with GERD for BE with endoscopic conﬁrmation,
compared with endoscopy screening only.METHODS: We incorporated data from a large clinical trial of Cytosponge performance into 2 validated
microsimulation models of EAC progression (the esophageal adenocarcinoma model from
Massachusetts General Hospital and the microsimulation screening analysis model from
Erasmus University Medical Center). The models were calibrated for US Surveillance, Epide-
miology and End Results data on EAC incidence and mortality. In each model, we simulated the
effect of a 1-time screen for BE in male patients with GERD, 60 years of age, using endoscopy
alone or Cytosponge collection of tissue, and analysis for the level of trefoil factor 3 with
endoscopic conﬁrmation of positive results. For each strategy we recorded the number of cases
of EAC that developed, the number of EAC cases detected with screening by Cytosponge only or
by subsequent targeted surveillance, and the number of endoscopies needed. In addition, we
recorded the cumulative costs (including indirect costs) incurred and quality-adjusted years of
life lived within each strategy, discounted at a rate of 3% per year, and computed incremental
cost-effectiveness ratios (ICERs) among the 3 strategies.RESULTS: According to the models, screening patients with GERD by Cytosponge with follow-up conﬁr-
mation of positive results by endoscopy would reduce the cost of screening by 27% to 29%
compared with screening by endoscopy, but led to 1.8 to 5.5 (per 1000 patients) fewer quality-
adjusted life years. The ICERs for Cytosponge screening compared with no screening ranged
from $26,358 to $33,307. For screening patients by endoscopy compared with Cytosponge the
ICERs ranged from $107,583 to $330,361. These results were sensitive to Cytosponge cost
within a plausible range of values.aper: BE, Barrett’s esophagus; BEST2,
ng Trial 2; EAC, esophageal adenocarci-
dication therapy; Erasmus/UW, micro-
model from Erasmus University Medical
Washington; GERD, gastroesophageal
ade dysplasia; ICER, incremental cost-
ophageal adenocarcinoma model from
al; PSA, probabilistic sensitivity analysis;
QALY, quality-adjusted life-year; RFA, radiofrequency ablation; SEER,
Surveillance, Epidemiology and End Results.
Most current article
© 2017 by the AGA Institute
1542-3565/$36.00
http://dx.doi.org/10.1016/j.cgh.2017.02.017
1398 Heberle et al Clinical Gastroenterology and Hepatology Vol. 15, No. 9CONCLUSIONS: In a comparative modeling analysis of screening strategies for BE in patients with GERD, we
found Cytosponge screening with endoscopic conﬁrmation to be a cost-effective strategy. The
greatest beneﬁt was achieved by endoscopic screening, but with an unfavorable cost margin.Keywords: Barrett’s Esophagus; Cost Effectiveness; Esophageal Adenocarcinoma; Cytosponge.Since 1975, the incidence of esophageal adenocar-cinoma (EAC) has increased more than 6-fold in
the United States, with comparable increases in several
other Western countries.1 The prognosis for diagnosed
esophageal cancer patients is poor, with 5-year relative
survival rates as low as 18.8%.1 Barrett’s esophagus
(BE) is a metaplastic precursor condition to EAC with
an estimated prevalence of 5.6%.2 BE can be detected
via endoscopy and may be managed with surveillance
to detect treatable high-grade dysplasia (HGD) or early
EAC. However, more than 90% of diagnosed EACs do
not arise from patients in BE surveillance programs.3
This statistic highlights the need for better strategies
for early detection to reduce the morbidity and mortality
associated with EAC.
Gastroesophageal reﬂux disease (GERD) symptoms
are a known risk factor for BE and EAC.4–6 GERD preva-
lence in the Western world has been estimated at 10% to
20%.7 Screening GERD patients for BE has the potential to
reduce EAC incidence, but costs of endoscopic screening in
a large population may be prohibitively high.
As a potential alternative to standard endoscopic
screening, we consider a novel minimally invasive
screening method, the Cytosponge (Medtronic, Dublin,
Ireland) which allows tissue to be sampled from the
surface of the esophagus nonendoscopically. A
biomarker, Trefoil factor 3, currently is used to diagnose
BE from the collected tissue.8–10 Cytosponge screening
may be available at a signiﬁcantly lower cost than
endoscopy and can be administered in a primary care
setting without the need for sedation.
A large clinical trial, Barrett’s oEsophagus Screening
Trial 2 (BEST2), to assess Cytosponge performance was
published, and we incorporated these latest data into our
modeling approach. We used a comparative modeling
approach with 2 previously validated models both cali-
brated to high-quality US population Surveillance,
Epidemiology and End Results (SEER) data on EAC
incidence and mortality.Methods
Cancer Intervention and Surveillance Modeling
Network–Esophageal Adenocarcinoma Models
Analyses were conducted using 2 independent
microsimulation models of the natural history of EAC:
the EAC model from Massachusetts General Hospital
(Boston, MA) (MGH model), and the microsimulation
screening analysis model from Erasmus UniversityMedical Center (Rotterdam, The Netherlands) and the
University of Washington (Seattle, WA) (Erasmus/UW
model). Both models incorporate the full natural history
of EAC, starting from normal health and progressing
through nondysplastic BE, low-grade dysplasia, and HGD
before reaching cancer. Both models have been cali-
brated previously to SEER data on EAC incidence and
mortality, stratiﬁed by age, year, and historic stage.11
During the calibration process, the MGH model approx-
imated the BE prevalence for males and females,
respectively, in 2010 to be approximately 2.6% and
1.1%; the Erasmus/UW model estimation was 1.4% and
0.5%.11 In addition, both models were extended in a
previous comparative modeling exercise to incorporate
detailed simulations of BE surveillance and treatment of
HGD using endoscopic eradication therapy (EET).12 The
models were developed independently and incorporate
different parameters and structural assumptions
regarding the natural history of EAC. However, the
models are part of the National Cancer Institute’s Cancer
Intervention and Surveillance Modeling Network con-
sortium and have undergone extensive comparative
modeling validation exercises. Full details of the
respective models are available online.13,14
Population of Interest
We simulated a 1950 birth cohort of US men starting
at age 20. At age 60, the population of interest was
restricted to those who had shown GERD symptoms and
had not been diagnosed with EAC. This group then was
screened for BE according to 1 of 3 strategies:
Cytosponge-ﬁrst screening, endoscopy-only screening, or
no screening. Patient cohorts in all strategies were fol-
lowed up until death or age 100. Quality-adjusted life-
years, EAC cases, EAC deaths, endoscopies, EET sessions,
and total lifetime costs of treatment and surveillance
were recorded starting from the time of the initial screen.
Screening Strategies
Three strategies were included in this analysis. In the
natural history or no-screening strategy, no intervention
took place until patients were found to have cancer
because of symptoms, at which point they received
standard treatment. In the Cytosponge screening strat-
egy, patients with GERD symptoms were given a 1-time
Cytosponge screen for BE at age 60. Patients with posi-
tive screening results were subject to conﬁrmation by
endoscopy. The false-negative and false-positive
September 2017 Cytosponge Screening of Barrett’s Esophagus 1399probabilities for the initial Cytosponge screen, condi-
tional on dysplastic grade, were derived from the BEST2
trial (Table 1). If either the Cytosponge test or the
conﬁrmation endoscopy was negative, there was no
further follow-up evaluation. In the endoscopic screening
strategy, GERD-symptomatic patients were given an im-
mediate diagnostic endoscopy at age 60. Performance
characteristics for endoscopy were estimated from
the literature (Table 1). Negative results received no
follow-up evaluation.Management of Barrett’s Esophagus
Detailed clinical aspects of BE surveillance and
endoscopic eradication therapy were incorporated into
our models in a previous analysis.12 For this analysis, we
assumed all patients diagnosed with HGD were treated
with endoscopic eradication that included possible
endoscopic mucosal resection and radiofrequency abla-
tion (RFA) therapy; touch-up RFA treatment was given to
patients who had dysplasia recurrence after initial
treatment. Possible outcomes of initial treatment were
complete eradication of BE (including dysplasia), eradi-
cation of dysplasia only, and treatment failure. Patients
with diagnosed low-grade dysplasia or nondysplastic BE
were not treated immediately, but underwent surveil-
lance at regular intervals (every year for low-gradeTable 1. Common Input Parameters
Parameter/model inputs Value Reference
Endoscopy parameters
BE ND false-negative rate 0.125 23
BE false-positive rate 0.075 23
Complication rate 0.00013 24,25
Endoscopy cost $745 26
Cytosponge parameters
Bleed rate 0.002 20a
BE false-negative rate (ND) 0.21 20
BE false-negative rate (LGD) 0.195 20
BE false-negative rate (HGD) 0.158 20
BE false-positive rate 0.076 20
Cost of Cytosponge $182 16b
Key RFA treatment parameters
RFA initial treatment cost $5630 26
RFA touch-up treatment cost $1012 26
Post-treatment recurrence rate 0.10 27,28
Eradication rate of dysplasia with
persistence of intestinal
metaplasia
HGD 0.17 27,28
LGD 0.19 27,28
Eradication rate of dysplasia and
intestinal metaplasia
HGD 0.68 27,28
LGD 0.72 27,28
ND 0.81 27,28
LGD, low-grade dysplasia; ND, no dysplasia.
aBleed rate estimated from adverse events reported in BEST2.
bPersonal communication with Medtronic representative Terry Davison,
June 29, 2016.dysplasia, and every 3 years for nondysplastic BE),
with treatment administered after a diagnosis of HGD.
This treatment and surveillance strategy is consistent
with recent American Gastroenterological Association
guidelines.15 Key parameters governing endoscopic
eradication treatment in the models can be found in
Table 1.
Costs
A cost-effectiveness analysis was conducted from a
societal perspective. Costs for cancer treatment were
derived from the literature. Costs for endoscopy and for
EET of BE with HGD were estimated using Medicare
reimbursement rates (Table 1). Because the Cytosponge
is a new technology and not yet available commercially,
there are little empiric data to inform its cost in a clinical
setting. For the base case we estimated an expected cost
of $182 based on a combination of direct communication
with Medtronic representatives regarding the cost of the
device itself (estimated as $55) as well as Medicare fa-
cility payments for comparable diagnostic tests.16 Given
the uncertainty of this parameter and its importance to
our analysis, we conducted a pivotal sensitivity analysis
using a wide range of plausible estimated Cytosponge
costs from $0 up to $1000.
Quality-of-Life Adjustments
Quality-of-life utilities for EAC by stage were esti-
mated from the literature, as were decrements for
endoscopy, EET, and complications including stricture or
perforation.
Outcomes
For each strategy we recorded the number of clinical
EAC cases developed, the number of EAC cases detected by
the initial screen or by subsequent targeted surveillance,
and the number of endoscopies needed. In addition, we
recorded the cumulative costs (including indirect costs)
incurred and quality-adjusted years of life lived within
each strategy, discounted at a rate of 3% per year, and
computed incremental cost-effectiveness ratios (ICERs)
between the 3 strategies. All outcomeswere computed per
1000 GERD-symptomatic patients at the start of screening.
Sensitivity Analyses
We performed 1-way sensitivity analyses on several
key parameters, including Cytosponge cost, Cytosponge
performance characteristics, initial effectiveness of EET,
rates of recurrence after EET, sex, and age at initial
screening. In addition, we performed a cost-effectiveness
analysis from an alternative perspective in which patient
time spent undergoing screening or treatment was
incorporated into the total cost. A detailed description of
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the Supplementary Materials and Methods section and
Supplementary Tables 1 and 2.
Finally, in the MGH model, a probabilistic sensitivity
analysis (PSA) was performed, simultaneously varying a
large number of parameters including performance
characteristics of Cytosponge and endoscopy, complica-
tion rates, recurrence rates, direct costs, and utilities.
Distributions for each parameter were estimated from the
literature. 1000 runs of 10 million patients each were
performed using parameter sets sampled from the esti-
mated distributions via a Metropolis algorithm. A distri-
bution for Cytosponge cost was not included in the PSA,
instead the Cytosponge cost was varied across the full $0
to $1000 range for each PSA run. Full details of the
probabilistic and 1-way sensitivity analyses can be found
in the Supplementary Materials and Methods section.
Results
Base Case
Detailed base-case results are shown in Table 2. The
natural history (no screening) strategy resulted in the
worst health outcomes, with 13.75 to 16.25 total cancers
and 15,076 to 15,078 quality-adjusted life-years (QALYs)
(ranges reﬂect differences between models). Endoscopic
screening offered the largest beneﬁt, with 6.8 to 12.44
total cancers and 15,101 to 15,116 QALYs. The
Cytosponge-ﬁrst screening showed results that were in-
between, with 8.18 to 13.15 cancers and 15,099 to
15,110 QALYs. However, greater beneﬁts were accom-
panied by higher total costs. Costs were $703,690 to
$762,043 using the natural history strategy, $1,485,205
to $1,597,713 using the Cytosponge strategy, and
$2,089,549 to $2,185,741 using the endoscopy strategy.
Both models found the Cytosponge to be cost effec-
tive compared with no screening in the base-case anal-
ysis, with an ICER of $26,358 to $33,307 (Figure 1). Both
models found that endoscopic screening was not cost
effective when Cytosponge-ﬁrst screening was available
as an alternative; the ICER for endoscopic screening
compared with the Cytosponge was $107,583 to
$330,361 greater than our willingness-to-pay thresholdTable 2.Main Results of the Simulation Models
MGH
Natural history Cytosponge
Total clinical EAC 16.25 8.82
Total screen-detected EAC 0.00 4.33
Total EAC 16.25 13.15
Endoscopies 0 757
Cost (discounted) $762,043 $1,485,205
QALY (discounted) 15,078 15,099
NOTE. All results are reported per 1000 GERD patients at the start of screening.of $100,000. The large cost difference between the
Cytosponge and endoscopic screening was driven pri-
marily by the total number of endoscopies needed. The
models predicted 757 to 1197 screening or surveillance
endoscopies would be needed using the Cytosponge
strategy, compared with 1826 to 2296 using the endo-
scopic screening strategy.
Sensitivity Analyses
Results of a 1-way sensitivity analysis on the Cyto-
sponge cost are shown in Figure 2. Endoscopic screening
becomes cost effective (given a $100,000 willingness-to-
pay-threshold) when the total cost of the Cytosponge
exceeds $604 (MGH) or $224 (Erasmus/UW). Further-
more, endoscopic screening is a dominant strategy when
the Cytosponge cost exceeds $684 (MGH) or $565
(Erasmus/UW). Thus, our results are sensitive to the
Cytosponge cost within the range deemed plausible for
this analysis; it is notable, however, that the Cytosponge
remains cost effective over a majority of this range.
Results of all other 1-way analyses are provided in
the Supplementary Materials and Methods section and
Supplementary Tables 3 and 4. In an analysis of
screening for 60-year-old women with GERD symptoms,
the Cytosponge remained cost effective (ICER,
$86,850–$89,674 compared with natural history)
despite the lower incidence of EAC in women. Endo-
scopic screening was strictly dominated in this analysis.
Our ﬁndings were somewhat sensitive to estimates of the
performance characteristics of the Cytosponge and RFA
characteristics. With low estimates of Cytosponge
sensitivity and speciﬁcity, the Cytosponge remains cost
effective (ICER, $29,172–$34,758). However, comparing
endoscopy with the Cytosponge we found an ICER of
$64,031 to $191,076, therefore endoscopy may be a
viable strategy given a willingness-to-pay threshold of
$100,000 if the diagnostic accuracy of the Cytosponge is
sufﬁciently poor. In addition, endoscopy may be viable if
the recurrence rates after EET are low or if the effec-
tiveness is high, with endoscopy to Cytosponge ICERS of
$83,686 to $314,574 and $98,227 to $303,055, respec-
tively. Our ﬁndings were robust to inclusion of indirect
costs, sex, and choice of initial screening age (ages, 50,Erasmus/UW
Endoscopy Natural history Cytosponge Endoscopy
7.09 13.75 5.13 3.06
5.35 0.00 3.05 3.74
12.44 13.75 8.18 6.8
1826 0 1197 2296
$2,089,549 $703,690 $1,597,713 $2,185,741
15,101 15,076 15,110 15,116
Figure 1. Cost/beneﬁt curves for the (A) MGH (blue) and (B) Erasmus/UW (green) models. All numbers are reported per 1000
GERD patients at the start of screening. NH, natural history.
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cost effective whereas endoscopic screening exceeded
the willingness-to-pay threshold.
Finally, a probabilistic sensitivity analysis was per-
formed using the MGH model. With a ﬁxed Cytosponge
cost of $182 and a willingness-to-pay threshold ﬁxed at
$100,000, our results were consistent across all runs.
The Cytosponge was found to be cost effective with an
ICER ranging from $32,567 to $36,353 compared with
natural history; endoscopic screening was not cost
effective with an ICER ranging from $234,762 to
$423,809 compared with the Cytosponge. When the
Cytosponge cost was increased to $500, the strategy
remained cost effective in all PSA runs, with an ICER
ranging from $47,326 to $51,822 compared with natural
history. The ICER for endoscopic screening compared
with the Cytosponge remained greater than the
willingness-to-pay threshold in all runs, ranging from
$106,630 to $206,272. Further details including alter-
nate analyses with other willingness-to-pay thresholds
and Cytosponge costs can be found in the Supplementary
Materials and Methods section, Supplementary Tables 2
and 3, and Supplementary Figures 1 to 4.Discussion
Our comparative modeling analysis found that, for
60-year-old men with GERD symptoms, an initial Cyto-
sponge screen may be a cost-effective way to reduce the
incidence and mortality of esophageal adenocarcinoma.
Cytosponge screening could result in signiﬁcant cost sav-
ings compared with screening with endoscopy. Theseﬁndings are consistent with those of a previous UK
modeling analysis that used preliminary Cytosponge
data.17
This cost savings is driven in part by the large dif-
ference in the estimated cost of a single endoscopy
compared with administration of a Cytosponge screen.
An additional driver of cost reduction in the Cytosponge
strategy is the reduction in the number of false-positive
results; although the estimated false-positive rate for
the Cytosponge was higher than that of endoscopy, the
combined false-positive rate for the Cytosponge with
endoscopic conﬁrmation was lower than that of a single
endoscopy. This lead to a reduction in the number of
people who entered surveillance and thus to the total
number of endoscopies and EET sessions.
A signiﬁcant strength of our analysis was the
comparative modeling approach. Although the 2 models
shared a number of common inputs (including costs of all
procedures, test performance characteristics, estimates of
EET effectiveness, and SEER incidence and mortality as
calibration targets), they were developed and calibrated
independently, used different mathematic methods, and
made different quantitative and structural assumptions
regarding the natural history of EAC development. For
example, the models relied on different estimates of BE
prevalence, and the Erasmus/UW model incorporated
regressionwhereas theMGHmodel did not. Although both
models were calibrated to SEER incidence data, this con-
strained only the overall progression rate to EAC in the
total population, leaving room for differences in the rela-
tive risk of BE or cancer development associated with
GERD symptoms. Detailed proﬁles of both models as well
as a broad comparative overview are available online.13,14
Figure 2. Sensitivity analysis of the Cytosponge cost performed with the MGH and Erasmus/UW models. ICERs corre-
sponding to the efﬁciency frontier are shown at each point.
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suggests a degree of robustness in our ﬁndings to the
uncertainties that these model differences represent.
In our analysis we have considered use of the Cyto-
sponge only as amethod ofﬁrst-line screening for BE using
the Trefoil factor 3 biomarker. We did not consider
Cytosponge-based surveillance strategies because BE
surveillance requires discrimination between nondys-
plastic BE, low-grade dysplasia, and HGD to determineappropriate surveillance intervals and treatment options.
Currently, this level of detail requires an endoscopic
diagnosis. However, with additional biomarkers or panels,
Cytosponge tissue collectionpotentially could allow for the
accurate identiﬁcation of dysplasia, which could alter the
role of the Cytosponge signiﬁcantly in EAC prevention.
We chose to compare the Cytosponge with no
screening or endoscopic screening because endoscopy
with biopsy is the current standard for BE diagnosis.
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ventional endoscopy such as unsedated transnasal
endoscopy and tethered capsule endoscopy are prom-
ising and potentially disruptive technologies that are
accruing clinical evidence and may be viable options in
the future.18,19
A signiﬁcant limitation of our analysis was the
dependence of our results on estimates of uncertain
parameters, including screening-related test perfor-
mance characteristics, complications, quality-of-life ad-
justments, and parameters governing the natural history
of EAC such as the independently optimized estimates of
BE prevalence during the development of each model. To
mitigate this limitation, we used the most reliable and
up-to-date parameter estimates available in the litera-
ture, and performed both 1-way sensitivity analysis and
probabilistic sensitivity analysis. Furthermore, our use of
a comparative modeling approach provided a check
against structural uncertainty in our knowledge of EAC
natural history.
Another limitation was the uncertainty regarding the
cost of the Cytosponge. It is possible that the cost of the
Cytosponge could be signiﬁcantly different from our
base-case estimate once implemented in clinical practice.
We addressed the limitation with multiple sensitivity
analyses, both 1-way and probabilistic (MGH only).
However, results continued to be robust at twice the cost
of the base-case estimate of $182; it is not until the cost
of the Cytosponge exceeds $684 (MGH) or $565 (Eras-
mus/UW) that endoscopy would become the dominant
strategy.
Our analysis did not incorporate adherence rates; we
assumed perfect compliance with the speciﬁed screening
strategies as well as with all follow-up surveillance and
treatment. Thus, the effectiveness of both the Cytosponge
and endoscopic screening likely were somewhat exag-
gerated in our models. In measures of acceptability, the
Cytosponge generally has outperformed endoscopy in
trials conducted to date.20–22 In addition, Cytosponge
screening can be performed in a brief outpatient visit,
compared with endoscopy, which in the United States
typically is performed with sedation. The Cytosponge
therefore may have higher adherence rates compared
with endoscopy, particularly among patients who have
difﬁculty taking time off from work or arranging post-
procedure transportation. Thus, in practice, the differ-
ences in effectiveness between the Cytosponge and
endoscopic screening may be smaller (or more favorable
to the Cytosponge) than estimated by our models.
Our analyses focused on cohorts of men with GERD
symptoms. Limited numbers of female patients in the
BEST2 study made it difﬁcult to inform the performance
characteristics of the Cytosponge for this cohort. None-
theless, we conducted a sensitivity analysis that indi-
cated that Cytosponge screening would be cost effective
for 60-year-old women with GERD symptoms. This
ﬁnding should be read as provisional until adequate data
become available to inform a more robust analysis.In conclusion, our comparative modeling analysis
found that a Cytosponge-ﬁrst strategy may be a cost-
effective way to screen for BE and reduce the harms
associated with esophageal adenocarcinoma in patients
with GERD symptoms. In addition, both models found
endoscopic screening to be a non–cost-effective
approach. These ﬁndings were consistent in both models
but were sensitive to the cost of the Cytosponge.Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
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Probabilistic Sensitivity Analysis
Overview. A PSA was conducted to assess the
robustness of our ﬁndings to uncertainty in model pa-
rameters. Parameter distributions were estimated from
the literature and expert opinion. Sets of parameters
were generated jointly from these distributions using the
Metropolis–Hastings algorithm1 to avoid parameter sets
with low combined probability. Ten thousand parameter
sets were generated; the last 1000 were used as inputs
to the MGH model for runs of 10 million patients each.
Cost-effectiveness calculations were performed for each
run, at various values of Cytosponge cost and willing-
ness-to-pay.
Estimation of parameter distributions. The distribu-
tions used in the PSA are listed in Supplementary
Table 1. Distributions are speciﬁed as Beta(a, b) or
normal(mean, SD).
The Barrett’s oEsophagus Screening Trial 2 (BEST2)
trial provided data that allowed us to ﬁt beta distributions
for Cytosponge performance characteristics directly. For
the performance characteristics of endoscopy, we used
point estimates found in the literature as means, and
ﬁtted distributions with variances based on the analogous
Cytosponge parameters. Distributions for utility adjust-
ments were based similarly on point estimates from the
literature, with variance calculated based only on the
order of magnitude of the point estimate.
We used conditional beta distributions for parame-
ters such as postrecurrence histology in which exactly
one of several possibilities must occur. This allowed us to
generate random values for the relevant probabilities
that are guaranteed to sum to 1.
Costs (with the exception of the Cytosponge) were
calculated based on Medicare reimbursement rates. We
assumed the variation in reimbursement rates was small
and used a SD of $25.
Results. Given a base-case price of $182 for the
Cytosponge and a willingness-to-pay threshold of
$100,000/QALY, the Cytosponge was cost effective and
endoscopy was beyond the willingness-to-pay threshold
in 100% of runs. The ICER for the Cytosponge compared
with natural history remained in a relatively small range
($32,567–$36,354), indicating that our results were
robust to the estimated uncertainties in the included
parameters. The ICER for endoscopy compared with the
Cytosponge ranged from $234,762 to $423,809.
For each PSA run, we chose a best strategy by ﬁrst
identifying the set of strategies that were cost effective
(ie, on the efﬁciency frontier with an ICER less than the
willingness-to-pay threshold), then selecting among
those the strategy that yielded the greatest number of
QALYs. By using these criteria, the Cytosponge was the
best strategy in 100% of runs with the ﬁxed values of
the Cytosponge cost and willingness-to-pay threshold
mentioned earlier.We conducted a further sensitivity analysis in which
the PSA was repeated at values of a Cytosponge cost
between $0 and $1000; for each cost point, we deter-
mined the proportion of runs in which the Cytosponge
endoscopy, or natural history was the best strategy.
These proportions are plotted in Supplementary
Figure 1. The Cytosponge was the best strategy in all
runs for every value of a Cytosponge cost less than $519.
If a Cytosponge cost more than $671, then endoscopy
was always the best strategy. Between these 2 values the
Cytosponge/endoscopy comparison was subject to
heightened uncertainty.
All previous analyses were conducted with a ﬁxed
willingness-to-pay threshold of $100,000. We examined
the impact of this threshold choice by varying the
willingness-to-pay threshold from $0 to $250,000, and
performing PSA at values in between. We plotted the
proportion of runs favoring each strategy at each point
in Supplementary Figure 2. Natural history was the
favored strategy if the willingness-to-pay threshold was
very low, between $0 and approximately $50,000.
Between $52,000 and $106,000 the Cytosponge was
favored in all PSA runs, whereas at greater than
$206,000 endoscopy always was favored, leaving a
sizable range of varying degrees of uncertainty. For
instance, at a willingness-to-pay threshold of $125,000,
the Cytosponge was favored 83% of the time, and
endoscopy was favored 17% of the time. At $150,000,
endoscopy was favored in a majority of runs (63%)
compared with the Cytosponge (37%). Thus, if the so-
cietal willingness-to-pay threshold is higher than esti-
mated in our base-case analysis, our ﬁndings may be
subject to considerable uncertainty.
One-Way Sensitivity Analyses
In addition to the PSA we performed multiple 1-way
sensitivity analyses on selected parameters, including
choice of screening cohort (male or female GERD pa-
tients; ages 50, 60, or 70 y), Cytosponge performance
characteristics, effectiveness and recurrence rates asso-
ciated with endotherapy, and inclusion or exclusion of
indirect patient time costs in total cost estimates. For
each analysis the effect on the ICERs of the Cytosponge
compared with natural history, endoscopy compared
with natural history, and endoscopy compared with the
Cytosponge are shown in Supplementary Tables 2 and 3.
Cytosponge and endoscopic eradication therapy
parameters. For Cytosponge speciﬁcity the upper and
lower bounds were taken from the 95% conﬁdence in-
tervals reported by the BEST2 trial.2 The exact param-
eter values used for this analysis as well as for the
probabilities of recurrence after EET and of initial EET
effectiveness are shown in Supplementary Table 4. In the
Erasmus/UW model, we found our results to be sensitive
to Cytosponge performance characteristics and EET
effectiveness and recurrence; endoscopy became cost
effective when the model was run with low estimates of
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EET recurrence, and high estimates of EET effectiveness.
In the MGH model, results were robust for all Cytosponge
and EET parameters.
Choice of screening cohort. The base-case population
cohort began by screening men with GERD symptoms at
age 60; we performed additional analyses of men at ages
50 and 70, and women at age 60, in each case screening
those with GERD. The Cytosponge remained cost effec-
tive for screening male GERD patients regardless of the
screening age considered, and endoscopy remained
non–cost effective. Both models concluded that for fe-
male GERD patients, implementing Cytosponge screening
at age 60 would be cost effective. The ICER for the
Cytosponge compared with natural history in this anal-
ysis was substantially higher (range, $86,850–$89,674)
than in the all-male base case, but remained less than the
willingness-to-pay threshold. This result should be read
as provisional because the data used to inform the
Cytosponge performance characteristics were based on a
predominantly male cohort.
Indirect costs. Large-scale screening efforts can
impose considerable time costs on patients (and poten-
tial escorts after sedation), including travel time, wait
time, the time of the procedure itself, and recovery time.
To capture the total burden of the interventions under
consideration more fully, we performed an alternative
analysis in which we incorporated estimates of patient
time costs for endoscopic screening, Cytosponge
screening, endoscopic eradication therapy, and treat-
ment for EAC. Time costs then were converted to US
dollars by multiplying by the US median wage of $17.40
per hour.3
Because estimates of EAC time cost are not directly
available, we used comparable estimates for gastric and
colorectal cancer as proxies. The patient time cost of
gastric cancer has been estimated at 351.3 hours in the
ﬁrst year after diagnosis and 512.2 hours in the ﬁnal year
of life; we adopted these as costs for the ﬁrst and last
year of EAC.4 For the time cost of care between the ﬁrst
and ﬁnal year of cancer, we followed a previous analysis
that assumed a monthly time cost equivalent to $27
(2007 dollars) for colorectal cancer.5 Adjusting for
inﬂation to the year 2015 yielded a monthly continuing
EAC cost of $31.16.
We assumed the time costs associated with an upper
endoscopy were comparable with those of colonoscopy
because the procedures are similar. A study of colonos-
copy time costs found that patients spent a median of 1.1
hours in transit, 2.8 hours at the center (including wait
and procedure time), and 17.7 hours from completion of
the procedure until returning to normal activity.6 It is
recommended that endoscopy patients arrange for a
friend or family member to transport them to and from
the facility. This imposes an additional time burden that
we accounted for by doubling the transit time and time
at the center. Finally, the recovery time was anoverestimate of patient time lost because it in some cases
included time the patient spent sleeping overnight. To
adjust for this, we adjusted the recovery time down by a
third, arriving at a total endoscopy time cost of 19.6
hours. Finally, we assumed the time cost of endoscopic
eradication therapy was the same as that of diagnostic
endoscopy.
The time cost of Cytosponge screening will depend on
its exact implementation within clinical practice; if
offered during an annual physical, the incremental time
cost may be negligible. As a conservative estimate, we
assumed Cytosponge screening would be offered as a
stand-alone intervention, so that the patient would spend
on average 1.1 hours traveling and 1.4 hours waiting,
similar to a colonoscopy patient.6 In contrast to colo-
noscopy or upper endoscopy, no sedation is required for
the Cytosponge procedure, therefore it is unnecessary for
anyone to accompany the patient. Finally, we assumed
the procedure time to be 0.3 hours, resulting in a total
time cost of 2.8 hours.
Cost-effectiveness results for this alternative analysis
including indirect cost are shown alongside the base-case
results in Supplementary Figures 3 and 4. Despite the
substantial effect this perspective has on procedure
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Supplementary Figure 4. Indirect cost and base case results
of the Erasmus/UW model.
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Supplementary Figure 1. Proportion of PSA runs favoring
each strategy by willingness-to-pay threshold, assuming a
ﬁxed willingness-to-pay ratio of $100,000 (MGH model).
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Supplementary Figure 2. Proportion of PSA runs favoring
each strategy by willingness-to-pay threshold, assuming a
ﬁxed Cytosponge cost of $182 (MGH model).
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Supplementary Figure 3. Indirect cost adjustment and base-
case results (MGH model).
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Supplementary Table 1. Probability Sensitivity Analysis Parameters and Distributions
Parameter Distribution Reference
Cytosponge parameters False positive beta(34, 411) 2
False-negative ND beta(78, 294) 2
False-negative LGD beta(14, 63) 2
False-negative HGD beta(16, 85) 2
Complication rate beta(2, 998) 2
Endoscopy parameters False negative beta(31, 214)
False positive beta(33, 405)
Cost Normal(745.36, 25) 7
Complication rate beta(275, 211,135) 8
RFA costs Cost of initial treatment Normal(5630, 25) 7
Cost of touch-ups Normal(1012, 25) 7
Histology after post–CE-IM recurrence
event by pre-RFA health state
Pre-RFA NDBE Postrecurrence NDBE beta(110, 9) 9,10
Postrecurrence LGDa beta(7, 2) 9,10
Postrecurrence HGDa beta(2.5, 0.5) 9,10
Postrecurrence EACa 9,10
Pre-RFA LGD Postrecurrence NDBE beta(78, 17) 9,10
Postrecurrence LGDa beta(13, 4) 9,10
Postrecurrence HGDa beta(2,2) 9,10
Postrecurrence EACa 9,10
Pre-RFA HGD Postrecurrence NDBE beta(64, 29) 9,10
Postrecurrence LGDa beta(14, 15) 9,10
Postrecurrence HGDa beta(9, 6) 9,10
Postrecurrence EACa 9,10
Probability of recurrence event after RFA
by pre-RFA health state
Pre-RFA NDBE beta(47, 621) 9,10
Pre-RFA LGD/IND beta(46, 437) 9,10
HGD beta(42, 374) 9,10
Effectiveness by pre-RFA health state
Pre-RFA HGD CE-D beta(607, 107) 11
CE-IM given CE-D beta(122, 485) 11
Pre-RFA LGD CE-D beta(581, 52) 11
CE-IM given CE-D beta(123, 458) 11
Pre-RFA NDBE CE-IM beta(941, 220) 11
Complications Perforation rate beta(5, 19,995) 11
Stricture rate beta(27, 513) 11
Quality-of-life adjustments Local EAC utility beta(46, 9)
Regional EAC utility beta(59, 31)
Distant EAC utility beta(38, 59)
Unstaged EAC utility beta(59, 35)
Post-treatment EAC utility beta(15, 1)
Endoscopy penalty beta(15, 7642)
EET or stricture penalty beta(132, 22,750)
Cancer costs Localized: ﬁrst year Normal(46,752, 2806.1224) 12
Localized: last year Normal(51,274, 3207.1428) 12
Regional: ﬁrst year Normal(59,667, 3835.7) 12
Regional: last year Normal(61,606, 2534.1836) 12
Distant: ﬁrst year Normal(45,303, 5572.9591) 12
Distant: last year Normal(67,526, 2826.0204) 12
Continuing care Normal(3102, 416.84) 12
Unstaged Average of local/regional/distant 12
CE-D, complete eradication of dysplasia; CE-IM, complete eradication of intestinal metaplasia; LGD, low-grade dysplasia; ND, no dysplasia; NDBE, no dysplasia
Barret’s esophagus.
aPost-recurrence histology probabilities were implemented as conditional b distributions. EAC histology probability was calculated as 1 minus the sum of
probabilities of the other states.
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Supplementary Table 2. Base Values and Sensitivity Parameters
Durability of successful treatment
Base value Lower value Upper value
Pretreatment
histology
Pretreatment
histology
Pretreatment
histology
NDBE LGD HGD NDBE LGD HGD NDBE LGD HGD
Annual recurrence probability 7.0% 10.7% 10.0% 3.5% 5.4% 5.0% 14.0% 21.5% 20.0%
Effectiveness of the initial treatment
Success of therapy in pretreatment HGD patients
CE–IM and CE-D 0.680 0.644 0.889
Non–CE-IM, CE-D 0.171 0.178 0.037
Success of therapy in pretreatment LGD patients
CE–IM and CE-D 0.724 0.678 0.981
Non–CE-IM, CE-D 0.194 0.211 0.000
Success of therapy in pretreatment ND patients
CE–IM 0.811 0.685 0.984
Non–CE-IM 0.189 0.315 0.016
Cytosponge performance characteristics
Speciﬁcity 92.4% 90.0% 95.0%
ND sensitivity 79.0% 74.5% 83.0%
LGD sensitivity 80.5% 69.9% 88.7%
HGD sensitivity 84.2% 75.6% 90.7%
CE-D, complete eradication of dysplasia; CE-IM, complete eradication of intestinal metaplasia; LGD, low-grade dysplasia; ND, no dysplasia.
Supplementary Table 3. Results of Sensitivity Analyses: MGH Model
Analysis
Cytosponge vs natural
history ICER, $
Endoscopy vs natural
history ICER, $
Endoscopy vs cytosponge
ICER, $
All female 89,674 211,332 Dominated
Cytosponge performance characteristics
Upper bound 32,168 56,391 823,979
Lower bound 34,758 56,391 191,076
Radiofrequency ablation effectiveness
Upper bound 31,564 53,720 303,055
Lower bound 41,981 70,579 547,718
Recurrence after radiofrequency ablation
Upper bound 34,709 58,480 346,459
Lower bound 32,380 54,952 314,574
Start: age 50 27,561 62,990 298,929
Start: age 70 45,435 74,279 722,430
Indirect costs 48,749 84,365 507,069
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Supplementary Table 4. Results of Sensitivity Analyses: Erasmus/UW Model
Analysis
Cytosponge vs natural
history ICER, $
Endoscopy vs natural
history ICER, $
Endoscopy vs cytosponge
ICER, $
All female 86,850 251,354 Dominated
Cytosponge performance characteristics
Upper bound 24,769 37,630 215,674
Lower bound 29,172 37,630 64,031
Radiofrequency ablation effectiveness
Upper bound 23,787 34,320 98,277
Lower bound 27,603 39,245 112,499
Recurrence after radiofrequency ablation
Upper bound 27,583 39,056 110,470
Lower bound 25,546 35,183 83,686
Start: age 50 21,664 37,653 127,320
Start: age 70 39,576 58,548 283,514
Indirect costs 40,934 58,689 168,871
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